| [1] |
Wilde B, van Paassen P, Witzke O, et al. New pathophysiological insights and treatment of ANCA-associated vasculitis [J]. Kidney Int, 2011, 79(6): 599-612.
|
| [2] |
Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis [J]. Nat Rev Rheumatol, 2017, 13(11): 683-692.
|
| [3] |
Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines [J]. Rheumatology (Oxford), 2020, 59(4): e24-e32.
|
| [4] |
Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [J]. N Engl J Med, 2020, 382(7): 622-631.
|
| [5] |
Pepper RJ, McAdoo SM, Moran SM, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis [J]. Rheumatology (Oxford), 2019, 58(2): 260-268.
|
| [6] |
Terrier B. Treatment of ANCA-associated vasculitides: certainties and controversies [J]. Nephrol Ther, 2019, Suppl 1: S7-S12.
|
| [7] |
Cortazar FB, Muhsin SA, Pendergraft WF, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis [J]. Kidney Int, 2017, 3(2): 394-402.
|
| [8] |
Hilhorst M, van Paassen P, Tervaert JW, et al. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis [J]. J Am Soc Nephrol, 2015, 26(10): 2314-2327.
|
| [9] |
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis [J]. N Engl J Med, 2013, 369(5): 417-427.
|
| [10] |
de Joode AAE, Sanders JSF, Puéchal X, et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data [J] Rheumatology (Oxford), 2017, 56(11): 1894-1901.
|
| [11] |
Mukheyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis [J]. Ann Rheum Dis, 2009, 68(3): 310-317.
|
| [12] |
Maritati F, Alberici F, Oliva E, et al. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial [J]. PLoS One, 2017，12(10): e018588010.
|
| [13] |
Jones RD, Hiemstra TF, Blockmans DE, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial [J]. Ann Rheum Dis, 2019, 78(3): 399-405.
|
| [14] |
Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis [J]. J Am Soc Nephrol, 2007, 18(7): 2180-2188.
|
| [15] |
Derebail VK, Falk RJ. ANCA-associated vasculitis - refining therapy with plasma exchange and glucocorticoids [J]. N Engl J Med, 2020, 382(7): 671-673.
|
| [16] |
Casal Moura M, Irazabal MV, Eirin A, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease [J]. J Am Soc Nephrol, 2020, 31(11): 2688-2704.
|
| [17] |
Mekel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis [J]. ACR Open Rheumatol, 2020, 2(11): 662-671.
|
| [18] |
Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis [J]. N Engl J Med, 2021, 384(7): 599-609.
|
| [19] |
Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis [J]. J Am Soc Nephrol, 2017, 28(9): 2756-2767.
|
| [20] |
胡剑，高春林，张沛，等. 抗中性粒细胞胞质抗体相关性血管炎发病机制及治疗的研究进展[J]. 中华肾脏病杂志，2020, 36(5): 412-416.
|
| [21] |
Gan PY, Steinmetz OM, Tan DS, et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis [J]. J Am Soc Nephrol, 2010, 21(6): 925-931.
|
| [22] |
Salant DJ. Podocyte expression of B7-1/CD80: is it a reliable biomarker for the treatment of proteinuric kidney diseases with abatacept [J]. J Am Soc Nephrol, 2016, 27(4): 963-965.
|
| [23] |
Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s) [J]. Ann Rheum Dis, 2014, 73(7): 1376-1379.
|
| [24] |
Berti A, Cavalli G, Campochiaro C, et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab [J]. Semin Arthritis Rheum, 2015, 45(1): 48-54.
|
| [25] |
Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis [J]. N Engl J Med, 2017, 376(20): 1921-1932.
|
| [26] |
Antonelou M, Michaëlsson E, Evans RDR, et al. Investigators therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage, and crescentic GN [J]. J Am Soc Nephrol, 2020, 31(2): 350-364.
|
| [27] |
McAdoo SP, Prendecki M, Tanna A, et al. Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model [J]. Kidney Int, 2020, 97(6): 1196-1207.
|
| [28] |
Hu P, Su H, Xiao H, et al. Kinin B1 receptor is important in the pathogenesis of myeloperoxidase-specific ANCA GN [J]. J Am Soc Nephrol, 2020, 31(2): 297-307.
|